Obviously Generex had short time periods better th
Post# of 36514
“The Company has concluded it will be far more time efficient to forego the second interim analysis and to analyze the data on 390 patients and to provide final data to the U.S. Food and Drug Administration, Health Canada, U.K.’s MHRA, and Philippines FDA, as soon as it is available.” Anna Gluskin would write that.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)